Workflow
南华基金管理有限公司关于以通讯方式召开南华瑞盈混合型 发起式证券投资基金基金份额持有人大会的公告

Meeting Basic Information - The South China Ruiying Mixed Initiation Securities Investment Fund will hold a meeting to discuss the proposal to amend the termination clause of the fund contract [1][2] - The meeting will be conducted via communication, with voting starting from August 13, 2025, to September 15, 2025 [1][3] - The voting will be sent to the fund management company at a specified address [1] Meeting Agenda - The main agenda for the meeting is to review the proposal regarding the amendment of the termination clause in the fund contract [2] Voting Process - Fund holders can fill out and submit paper ballots, which can be downloaded from the fund management company's website or the China Securities Regulatory Commission's electronic disclosure website [4][5] - Specific requirements for individual and institutional investors regarding the submission of ballots are outlined [5][10] Authorization - Fund holders can authorize others to vote on their behalf, with specific rules for authorization outlined [8][9] - The authorization process allows for both paper and electronic methods, with detailed instructions provided for each [10][11] Counting Votes - The counting of votes will be supervised by designated personnel and conducted within two working days after the voting deadline [16] - Each fund share represents one vote, and specific conditions for the validity of ballots are established [16][17] Resolution Effectiveness - The proposal requires at least two-thirds of the voting rights held by participating fund holders to pass [18] - The decisions made during the meeting will be reported to the China Securities Regulatory Commission within five days [19] Second Meeting and Authorization - If the meeting does not meet the required quorum, a second meeting may be convened within three to six months [20] - Authorizations made for the first meeting will remain valid unless changed [20] Important Contacts - The meeting is organized by Nanhua Fund Management Co., with contact details provided for inquiries [21]